Patents by Inventor Dana Ferraris

Dana Ferraris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia
    Patent number: 11459313
    Abstract: The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, MCDANIEL COLLEGE
    Inventors: Ashkan Emadi, Rena G. Lapidus, Brandon A. Carter-Cooper, Steven Fletcher, Dana Ferraris, Edward A. Sausville
  • AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA
    Publication number: 20200283417
    Abstract: The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.
    Type: Application
    Filed: October 5, 2017
    Publication date: September 10, 2020
    Inventors: Ashkan Emadi, Rena G. Lapidus, Brandon A. Carter-Cooper, Steven Fletcher, Dana Ferraris, Edward A. Sausville
  • Compounds and methods of use thereof for treating neurodegenerative disorders
    Patent number: 9382229
    Abstract: Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: July 5, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Donald J. Zack, Cynthia Berlinicke, Laszlo Hackler, Zhiyong Yang, Joseph P. Steiner, Tomas Vojkovsky, Dana Ferraris, Barbara S. Slusher, James Inglese
  • Compositions and methods for treating cancer
    Patent number: 9040501
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 26, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Sergel Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • Compositions and Methods for Treating Cancer
    Publication number: 20140221305
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Application
    Filed: November 14, 2013
    Publication date: August 7, 2014
    Applicant: Eisai Inc.
    Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS
    Publication number: 20140187540
    Abstract: Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.
    Type: Application
    Filed: February 15, 2012
    Publication date: July 3, 2014
    Applicant: The Johns Hopkins University
    Inventors: Donald J. Zack, Cynthia Berlinicke, Laszlo Hackler, Zhiyong Yang, Joseph P. Steiner, Tomas Vojkovsky, Dana Ferraris, Barbara S. Slusher, James Inglese
  • Compositions and methods for treating cancer
    Patent number: 8609631
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 17, 2013
    Assignee: Eisai Inc.
    Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • Compositions and methods for treating cancer
    Patent number: 8329666
    Abstract: Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: December 11, 2012
    Assignee: Eisai Inc.
    Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • Compositions and methods for treating cancer
    Patent number: 8329665
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: December 11, 2012
    Assignee: Eisai Inc.
    Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • Compositions and methods for treating cancer
    Patent number: 8324180
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: December 4, 2012
    Assignee: Eisai Inc.
    Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20100279977
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Application
    Filed: April 6, 2010
    Publication date: November 4, 2010
    Applicant: EISAI INC.
    Inventors: Sergei BELYAKOV, Bridget DUVALL, Dana FERRARIS, Gregory HAMILTON, Mark VAAL
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20100279966
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Application
    Filed: April 6, 2010
    Publication date: November 4, 2010
    Applicant: EISAI INC.
    Inventors: Sergei BELYAKOV, Bridget DUVALL, Dana FERRARIS, Gregory HAMILTON, Mark VAAL
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20100279967
    Abstract: Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.
    Type: Application
    Filed: April 6, 2010
    Publication date: November 4, 2010
    Applicant: EISAI INC.
    Inventors: Sergei BELYAKOV, Bridget DUVALL, Dana FERRARIS, Gregory HAMILTON, Mark VAAL
  • Compounds and their uses
    Publication number: 20060142266
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: February 21, 2006
    Publication date: June 29, 2006
    Applicant: MGI GP, Inc.
    Inventors: Dana Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang
  • Compounds and their uses
    Publication number: 20060003987
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: August 30, 2005
    Publication date: January 5, 2006
    Applicant: Guilford Pharmaceuticals, Inc.
    Inventors: Dana Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang
  • Compounds and their uses
    Publication number: 20050148575
    Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
    Type: Application
    Filed: February 28, 2005
    Publication date: July 7, 2005
    Applicant: Guilford Pharmaceuticals Inc.
    Inventors: Dana Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang